1. A novel administration route for edaravone: I. Effects of metabolic inhibitors on skin permeability of edaravone
- Author
-
Toshiaki Sato, Keizo Mizuno, and Fumiyoshi Ishii
- Subjects
Male ,Antioxidant ,Skin Absorption ,medicine.medical_treatment ,Rats, Hairless ,Pharmaceutical Science ,Pharmacology ,Administration, Cutaneous ,Permeability ,chemistry.chemical_compound ,Pharmacokinetics ,Edaravone ,medicine ,Animals ,Transdermal ,chemistry.chemical_classification ,integumentary system ,Chemistry ,Proadifen ,Metabolism ,Diclofenac Sodium ,Permeation ,Rats ,Biochemistry ,Thiol ,Antipyrine - Abstract
We examined the effects of metabolic inhibitors on skin permeation of edaravone. SKF-525A, diclofenac sodium (DIC) and indomethacin (IND) were added to supernatant fluid (SF) of hairless rat (HR) skin homogenate. L-Cysteine (L-Cys) and benzotriazole (BTA), as pharmaceutical additives, were added to HR skin homogenate SF, and incubated at 37 degrees C for 30 min. K(m) and V(max) values were calculated. For determination of edaravone skin permeation from edaravone/hydroxypropyl-beta-cyclodextrin (HPbetaCD) complex solution, HR skin was placed in a Franz diffusion cell, and kept at 37 degrees C. Edaravone/HPbetaCD solution that contained L-Cys was put into the donor side. The relative activity in skin homogenate SF after co-treatment with IND and SKF-525A decreased to 40.8% of the control. However, DIC and IND had a weak inhibitory effect. For inhibition of edaravone metabolism, L-Cys and BTA had no effect on K(m) value, but V(max) was significantly decreased compared with controls (*P
- Published
- 2009
- Full Text
- View/download PDF